Advanced glycation in diabetic patients leads to cataracts

Article

The higher level of advanced glycation end products (AGE) in senile diabetic patients may correlate to a higher rate of cataract development, according to a study published in the May?June 2008 issue of the Journal of Diabetes and its Complications.

The higher level of advanced glycation end products (AGE) in senile diabetic patients may correlate to a higher rate of cataract development, according to a study published in the May–June 2008 issue of the Journal of Diabetes and its Complications.

Anjuman Gul, MBBS, MPhil of the Department of Biochemistry, Ziauddin University, Pakistan and colleagues performed a noncompetitive enzyme linked immunosorbent assay (ELISA) with a polyclonal anti-AGE antibody to study AGE immunoreactivity and investigate the link between AGE and cataract formation. Four senile study groups were assessed: non-diabetic non-cataract subjects (n=31); diabetic non-cataract subjects (n=33); diabetic cataract subjects (n=30); and non-diabetic cataract subjects (n=30). A fifth group (young non-diabetic non-cataract subjects; n=31) was also included in the evaluation.

Amongst the four senile groups, diabetic patients had significantly increased levels of fasting blood glucose, glycosylated haemoglobin and serum fructosamine when compared with non-diabetic patients, regardless of the presence (or non-presence) of cataracts. Cataract patients had significantly increased levels of serum AGEs compared with non-cataract patients; diabetic subjects also had increased serum AGE levels, but these were higher in those with cataracts than those without. Young patients had significantly lower AGE levels than any other group.

Thus the researchers concluded that senile diabetic subjects are prone to cataract development because of the distribution of AGEs in these subjects. This reinforces the theory that the advanced glycation process may have a role in cataract formation.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.